Purpose of review: The assessment of clinical efficacy of immunotherapy in patients with respiratory allergy is highly affected by variability and lack of validated outcome measures such as symptom and medication scores. At the same time, there is a need to identify reliable predictive surrogate markers or biomarkers that may correlate with real clinical endpoints and lead to individually tailored immunotherapy treatment. Recent findings In-vivo markers, such as early and late skin reaction as well as immunological parameters such as IgE levels, IgG subclasses, mucosal IgA, lymphocyte subsets, cytokines and local and systemic inflammatory markers, have been proposed as potential surrogate markers. Summary: Given the poor reproducibility and surrogacy to clinical outcomes shown in various clinical trials, the decreased availability in daily practice and anticipated high costs, an ideal surrogate marker is still not available to allergists.

An evidence-based appraisal of the surrogate markers of efficacy of allergen immunotherapy / Senna, G. E.; M., Calderon; M., Makatsori; Ridolo, Erminia; G., Passalacqua. - In: CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY. - ISSN 1528-4050. - 11:(2011), pp. 375-380. [10.1097/ACI.0b013e328348a7cd]

An evidence-based appraisal of the surrogate markers of efficacy of allergen immunotherapy.

RIDOLO, Erminia;
2011-01-01

Abstract

Purpose of review: The assessment of clinical efficacy of immunotherapy in patients with respiratory allergy is highly affected by variability and lack of validated outcome measures such as symptom and medication scores. At the same time, there is a need to identify reliable predictive surrogate markers or biomarkers that may correlate with real clinical endpoints and lead to individually tailored immunotherapy treatment. Recent findings In-vivo markers, such as early and late skin reaction as well as immunological parameters such as IgE levels, IgG subclasses, mucosal IgA, lymphocyte subsets, cytokines and local and systemic inflammatory markers, have been proposed as potential surrogate markers. Summary: Given the poor reproducibility and surrogacy to clinical outcomes shown in various clinical trials, the decreased availability in daily practice and anticipated high costs, an ideal surrogate marker is still not available to allergists.
2011
An evidence-based appraisal of the surrogate markers of efficacy of allergen immunotherapy / Senna, G. E.; M., Calderon; M., Makatsori; Ridolo, Erminia; G., Passalacqua. - In: CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY. - ISSN 1528-4050. - 11:(2011), pp. 375-380. [10.1097/ACI.0b013e328348a7cd]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2351277
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 16
social impact